Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Cellular's schizophrenia drug meeting trial goals, Britain's new mpox variant detection, proposed UK smoking bans, challenges in weight-loss medication access, CVS Health's strategy adaptation, South ...

BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...

Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...

For years, due to untreated schizophrenia, I refused housing, preferring to be homeless. When dealing with the severely ...

Penny, 25, of Suffolk County, L.I., has pleaded not guilty to second-degree manslaughter and criminally negligent homicide ...

A new drug could be a breakthrough in treating schizophrenia. Here's how it's different from current treatments.